AI-aided kidney care rolls into the Salt Lake State

Intermountain Healthcare has opened an AI-powered service line for patients with chronic kidney disease and end-stage renal disease.

The Utah-based organization launched the program and clinic Sept. 5 with aims of reducing hospital admissions 50%, slowing the progression of renal disease in those who have it and avoiding the need for emergency services due to renal failure.

The announcement comes from SymphonyRM, which is supplying the AI-based software supporting the program.

The company says its platform will help care coordinators manage interrelated factors that can affect outcomes. These include comorbid conditions, health-affecting behaviors and social determinants of health.

Suji Lee, MD, Intermountain’s medical director of kidney services, says the AI algorithms will “allow us to engage and connect patients to care earlier in their journey and effectively manage longitudinal care across the continuum,” which the organization believes will “empower patients to take a more active role in their own healthcare to improve outcomes while lowering costs.”

Intermountain Healthcare runs 24 hospitals and 215 clinics in Utah and Idaho.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.